GT Biopharma Inc. Logo

GT Biopharma Inc. (GTBP)

NASDAQ

Currency in USD
7.16
-0.33 (-4.41%)

Closed

Sep 18, 2026

Day's Range

7.11
7.52

52 wk Range

0.2220
11.98

Profile - GTBP - GT Biopharma Inc.

Profile

Mic Code

XNCM

Sector

Healthcare

Industry

Biotechnology

Employees

1


GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies built around its proprietary TriKE platform. The company develops NK cell engager-based candidates designed to help natural killer cells recognize and attack cancer cells, supporting research in hematologic malignancies, solid tumors, and autoimmune conditions. Its current pipeline includes programs such as GTB-3650, GTB-5550, and GTB-7550, which reflect the company’s emphasis on targeted biologic therapies that work through immune cell engagement rather than traditional chemotherapy approaches. GT Biopharma’s work is centered on advancing novel cancer and immune-modulating treatments through product development, clinical research, and commercialization efforts in the biotechnology market.

Profile Details

Type

Common Stock

Address

315 Montgomery Street

City

San Francisco

State

CA

Zip

94104

Country

United States

Phone

415 919 4040

Key Executives - GTBP - GT Biopharma Inc.

Key executives

NamePositionAgePay
Mr. Michael Martin Breen L.L.B.President, CEO & Executive Chairman621.38M
Mr. Alan Louis Urban CPACFO & Secretary57626.31K

Cross Listings - GTBP - GT Biopharma Inc.

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Charting by TradingView.

Last updated:

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.